Mirella Mashiach is a founding partner of Mesia Ventures, a venture capital firm set on transforming the way we build and invest in Bio companies. Mesia creates and invests in companies that use biology as a coding platform, to solve real-life challenges.
Mirella is a veteran of the Bio industry with unparalleled outlook on investments, portfolio management, and venture building. Her diverse career includes managing a corporate venture fund, heading dozens of strategic partnerships, and being director in startup boards.
Prior to co-founding Mesia Ventures, Mirella spent several years as an executive at Teva Pharmaceuticals, one of the world’s largest pharmaceutical companies, including as Managing Director of the company’s venture capital arm. During her tenure, Mirella also established the firm’s global alliances function. Mirella managed Teva’s investment portfolio into early- and late-stage opportunities and into other venture capital funds and sat on the board of startup biotech companies.
Along with her degree in Law, she holds an MA in Philosophy and a B.Sc. in Computer Science, all from Tel Aviv University.